{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T17:53:47Z","timestamp":1759773227965,"version":"3.41.2"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Digit. Health"],"abstract":"<jats:p>Spravato and other drugs with consciousness-altering effects show significant promise for treating various mental health disorders. However, the effects of these treatments necessitate a substantial degree of patient monitoring which can be burdensome to healthcare providers and may make these treatments less accessible for prospective patients. Continuous passive monitoring via digital devices may be useful in reducing this burden. This proof-of-concept study tested the MindMed Session Monitoring System\u2122 (MSMS\u2122), a continuous passive monitoring system intended for use during treatment sessions involving pharmaceutical products with consciousness-altering effects. Participants completed 129 Spravato sessions with MSMS at an outpatient psychiatry clinic specializing in Spravato treatment. Results indicated high rates of data quality and self-reported usability among participants and health care providers (HCPs). These findings demonstrate the potential for systems such as MSMS to be used in consciousness-altering treatment sessions to assist with patient monitoring.<\/jats:p>","DOI":"10.3389\/fdgth.2023.1281529","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T05:52:36Z","timestamp":1701237156000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating passive physiological data collection during Spravato treatment"],"prefix":"10.3389","volume":"5","author":[{"given":"Todd M.","family":"Solomon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matus","family":"Hajduk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Majernik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamileh","family":"Jemison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Deschamps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna","family":"Scoggins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Kolar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Am\u00e1vel","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Dubec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ondrej","family":"Skala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owen","family":"Muir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Tinkelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Barrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","article-title":"Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic","volume":"398","author":"Santomauro","year":"2021","journal-title":"Lancet"},{"year":"","key":"B2"},{"year":"","key":"B3"},{"key":"B4","doi-asserted-by":"publisher","first-page":"204512532091665","DOI":"10.1177\/2045125320916657","article-title":"Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers","volume":"10","author":"Matveychuk","year":"2020","journal-title":"Ther Adv Psychopharmacol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1097\/ALN.0b013e3181ed09a2","article-title":"Taming the ketamine tiger","volume":"113","author":"Domino","year":"2010","journal-title":"Anesthesiology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.biopsych.2012.05.003","article-title":"Ketamine for depression: where do we go from here?","volume":"72","author":"Aan Het Rot","year":"2012","journal-title":"Biol Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40261-022-01193-z","article-title":"Efficacy and safety of subcutaneous esketamine in the treatment of suicidality in Major depressive disorder and bipolar depression","volume":"42","author":"Surjan","year":"2022","journal-title":"Clin Drug Investig"},{"key":"B8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/13651501.2022.2030757","article-title":"Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme","volume":"26","author":"Samalin","year":"2022","journal-title":"Int J Psychiatry Clin Pract"},{"key":"B9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","article-title":"Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study)","volume":"319","author":"Martinotti","year":"2022","journal-title":"J Affect Disord"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2217\/cer-2022-0149","article-title":"Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study","volume":"11","author":"Brendle","year":"2022","journal-title":"J Comp Eff Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jagp.2023.06.016","article-title":"Investigating the effectiveness and tolerability of intranasal esketamine among older adults with treatment-resistant depression (TRD): a post-hoc analysis from the REAL-ESK study group","volume":"31","author":"d\u2019Andrea","year":"2023","journal-title":"Am J Geriatr Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/bdi.13296","article-title":"Treating bipolar depression with esketamine: safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression","volume":"25","author":"Martinotti","year":"2023","journal-title":"Bipolar Disord"},{"key":"B13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.euroneuro.2023.04.011","article-title":"Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: a viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study","volume":"74","author":"Chiappini","year":"2023","journal-title":"Eur Neuropsychopharmacol"},{"year":"","author":"Taylor","first-page":"P","key":"B14"},{"key":"B15","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/14737175.2019.1640604","article-title":"Esketamine for treatment resistant depression","volume":"19","author":"Swainson","year":"2019","journal-title":"Expert Rev Neurother"},{"year":"","key":"B16"},{"year":"","key":"B17"},{"year":"2019","key":"B18"},{"key":"B19","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol Rev"},{"key":"B20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/hup.348","article-title":"Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies","volume":"16","author":"Liechti","year":"2001","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"B21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry & the psychedelic drugs. Past, present & future","volume":"142","author":"Rucker","year":"2018","journal-title":"Neuropharmacology"},{"year":"2023","author":"Farchione","key":"B22"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e29167","DOI":"10.7759\/cureus.29167","article-title":"The use of psychedelics in the treatment of medical conditions: an analysis of currently registered psychedelics studies in the american drug trial registry","volume":"14","author":"Kurtz","year":"2022","journal-title":"Cureus"},{"key":"B24","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/d41586-021-00187-9","article-title":"How ecstasy and psilocybin are shaking up psychiatry","volume":"589","author":"Tullis","year":"2021","journal-title":"Nature"},{"year":"","key":"B25"},{"key":"B26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/978-981-15-2160-7_8","article-title":"Polysomnography","volume-title":"Bio-information for hygiene","author":"Kinoshita","year":"2021"},{"key":"B27","doi-asserted-by":"publisher","first-page":"383","DOI":"10.4093\/dmj.2019.0121","article-title":"Continuous glucose monitoring sensors for diabetes management: a review of technologies and applications","volume":"43","author":"Cappon","year":"2019","journal-title":"Diabetes Metab J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cvdhj.2020.03.001","article-title":"Atrial fibrillation monitoring with wrist-worn photoplethysmography-based wearables: state-of-the-art review","volume":"1","author":"Eerik\u00e4inen","year":"2020","journal-title":"Cardiovasc Digit Health J"},{"key":"B29","doi-asserted-by":"publisher","first-page":"12081","DOI":"10.1038\/s41598-022-15874-4","article-title":"Reliability and validity of the Roche PD mobile application for remote monitoring of early Parkinson\u2019s disease","volume":"12","author":"Lipsmeier","year":"2022","journal-title":"Sci Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"662811","DOI":"10.3389\/fdgth.2021.662811","article-title":"Wearable, environmental, and smartphone-based passive sensing for mental health monitoring","volume":"3","author":"Sheikh","year":"2021","journal-title":"Front Digit Health"},{"key":"B31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1146\/annurev-clinpsy-032816-044949","article-title":"Personal sensing: understanding mental health using ubiquitous sensors and machine learning","volume":"13","author":"Mohr","year":"2017","journal-title":"Annu Rev Clin Psychol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41746-021-00548-8","article-title":"Digital health tools for the passive monitoring of depression: a systematic review of methods","volume":"5","author":"De Angel","year":"2022","journal-title":"NPJ Digit Med"},{"key":"B33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/978-3-319-32270-4_6","article-title":"Prosodic analysis of speech and the underlying mental state","volume-title":"Pervasive computing paradigms for mental health","author":"Kliper","year":"2016"},{"year":"2015","author":"Yancheva","first-page":"134","key":"B34"},{"key":"B35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1023\/A:1024465317902","article-title":"Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS)","volume":"11","author":"Bremner","year":"1998","journal-title":"J Trauma Stress"},{"key":"B36","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/00004714-199008000-00003","article-title":"Validity and reliability of the observer\u2019s assessment of alertness\/sedation scale: study with intravenous midazolam","volume":"10","author":"Chernik","year":"1990","journal-title":"J Clin Psychopharmacol"},{"year":"","author":"Haichin","key":"B37"},{"year":"","key":"B38"},{"key":"B39","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000223730","article-title":"Exercise and mental health: many reasons to move","volume":"59","author":"Deslandes","year":"2009","journal-title":"Neuropsychobiology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.47626\/2237-6089-2021-0237","article-title":"Physical activity, exercise, and mental disorders: it is time to move on","volume":"43","author":"Schuch","year":"2021","journal-title":"Trends Psychiatry Psychother"}],"container-title":["Frontiers in Digital Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2023.1281529\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T05:52:41Z","timestamp":1701237161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2023.1281529\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":40,"alternative-id":["10.3389\/fdgth.2023.1281529"],"URL":"https:\/\/doi.org\/10.3389\/fdgth.2023.1281529","relation":{},"ISSN":["2673-253X"],"issn-type":[{"type":"electronic","value":"2673-253X"}],"subject":[],"published":{"date-parts":[[2023,11,29]]},"article-number":"1281529"}}